- Top-Line Results of a Phase 2b in Alzheimer’s On Track for Mid-Year 2020 - - Cash Balance Exceeds $26 Million at January 31, 2020 - - $5 Million Net Cash Use Expected in 2020 - AUSTIN, Texas , March 26, 2020 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc.
Approximately 100 Study Participants Will Receive PTI-125 For 12 Months AUSTIN, Texas , March 25, 2020 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced the initiation of an open-label extension study to
AUSTIN, Texas , March 19, 2020 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced clinical updates and business progress across its pipeline of product candidates under development.
AUSTIN, Texas , Feb. 11, 2020 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA ), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that The Journal of Prevention of Alzheimer’s Disease (JPAD), a peer-reviewed journal for the research community,
Top-Line Results Expected Mid-year 2020 AUSTIN, Texas , Jan. 28, 2020 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA ), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced it has initiated dosing for the last patient in a Phase 2b study of PTI-125.
- New Data Shows Clinical Evidence of Target Engagement and Target Validation – - Company Expects Data Publication in a Peer-reviewed Medical Journal – AUSTIN, Texas , Dec. 05, 2019 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA ), a clinical-stage biopharmaceutical company focused on
AUSTIN, Texas , Oct. 24, 2019 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA ), a clinical-stage biopharmaceutical company focused on Alzheimer’s disease, today announced that clinical results of its Phase 2a study of PTI-125 have been selected as a late-breaking oral presentation by the
First two patients dosed with lead drug candidate, PTI-125 Study initiation follows positive Phase 2a results demonstrating 100% response rate AUSTIN, Texas , Sept. 16, 2019 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA ), a clinical-stage biopharmaceutical company focused on
Lead drug candidate, PTI-125, significantly decreased key biomarkers of neuroinflammation and neurodegeneration in all study patients (p<.001 clinical="" data="" support="" initiation="" of="" a="" phase="" study="" in="" alzheimer="" q3="" austin="" texas="" sept.="" newswire="" cassava="" sciences="" inc.="">
